Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | Casein kinase II | 0.0772 | 0.3983 | 1 |
Trypanosoma cruzi | casein kinase II, putative | 0.0772 | 0.3983 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0772 | 0.3983 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0772 | 0.3983 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0772 | 0.3983 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0772 | 0.3983 | 0.5 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.1818 | 1 | 1 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.1818 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CK2 protein kinase | 0.0772 | 0.3983 | 0.0905 |
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.0772 | 0.3983 | 0.5 |
Echinococcus granulosus | proto oncogene serine:threonine protein kinase | 0.1818 | 1 | 1 |
Entamoeba histolytica | casein kinase, putative | 0.0772 | 0.3983 | 0.5 |
Plasmodium vivax | unspecified product | 0.0772 | 0.3983 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1818 | 1 | 1 |
Giardia lamblia | Kinase, CMGC CK2 | 0.0772 | 0.3983 | 0.5 |
Onchocerca volvulus | Serine\/threonine protein kinase homolog | 0.1818 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0772 | 0.3983 | 0.5 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.0772 | 0.3983 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0772 | 0.3983 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0772 | 0.3983 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0772 | 0.3983 | 0.5 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.0772 | 0.3983 | 0.5 |
Echinococcus multilocularis | proto oncogene serine:threonine protein kinase | 0.1818 | 1 | 1 |
Leishmania major | casein kinase II, putative | 0.0772 | 0.3983 | 0.5 |
Brugia malayi | Serine/threonine-protein kinase Pim-3 | 0.1818 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 0.75 uM | Cytotoxicity against human MRC5 cells assessed as cell viability after 7 days by Alamar blue assay | ChEMBL. | 23518280 |
IC50 (functional) | = 0.25 uM | Antiprotozoal activity against epimastigote form of Trypanosoma cruzi Tulahuen 2 assessed as parasite growth inhibition measured at day 5 | ChEMBL. | 23518280 |
IC50 (functional) | = 0.25 uM | Antiprotozoal activity against trypomastigote form of Trypanosoma brucei rhodesiense STIB900 assessed as parasite growth inhibition after 72 hrs by Alamar blue assay | ChEMBL. | 23518280 |
IC50 (functional) | = 0.56 uM | Antiprotozoal activity against trypomastigote form of Trypanosoma brucei brucei 427 assessed as parasite growth inhibition | ChEMBL. | 23518280 |
IC50 (functional) | = 5.08 uM | Antiprotozoal activity against amastigote form of Leishmania infantum MHOM/MA(BE)/67 infected in mouse peritoneal macrophages assessed as reduction of intracellular parasite burden after 5 days by Giemsa staining method | ChEMBL. | 23518280 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Trypanosoma cruzi | ChEMBL23 | 23518280 | |
Leishmania infantum | ChEMBL23 | 23518280 | |
Trypanosoma brucei gambiense | 23518280 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.